Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease
From BugSigDB
(Redirected from Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease)
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Rosario D, Bidkhori G, Lee S, Bedarf J, Hildebrand F, Le Chatelier E, Uhlen M, Ehrlich SD, Proctor G, Wüllner U, Mardinoglu A, Shoaie S
Journal
Cell reports
Year
2021
Keywords:
Parkinson’s disease, gut microbiota, gut-brain axis, metabolic modeling, metagenomics
Parkinson's disease (PD) is the most common progressive neurological disorder compromising motor functions. However, nonmotor symptoms, such as gastrointestinal (GI) dysfunction, precede those affecting movement. Evidence of an early involvement of the GI tract and enteric nervous system highlights the need for better understanding of the role of gut microbiota in GI complications in PD. Here, we investigate the gut microbiome of patients with PD using metagenomics and serum metabolomics. We integrate these data using metabolic modeling and construct an integrative correlation network giving insight into key microbial species linked with disease severity, GI dysfunction, and age of patients with PD. Functional analysis reveals an increased microbial capability to degrade mucin and host glycans in PD. Personalized community-level metabolic modeling reveals the microbial contribution to folate deficiency and hyperhomocysteinemia observed in patients with PD. The metabolic modeling approach could be applied to uncover gut microbial metabolic contributions to PD pathophysiology.
Experiment 1
Needs review
Curated date: 2024/03/09
Curator:
Revision editor(s):
Subjects
- Location of subjects
- Germany
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Patients with Parkinson's Disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patient with Early-stage L-DOPA-Naive Parkinson's Disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 11
- Group 1 sample size Number of subjects in the case (exposed) group
- 26
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- N/A
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Signature 1
Reviewed Marked as Reviewed by Peace Sandy on 2024-4-9
Source: Figure S1
Description: Representation of the most significant (FDR < 0.01) classified taxonomic alterations between Parkinson’s disease (PD) and controls.
Abundance in Group 1: increased abundance in
Revision editor(s): Raihanat, Peace Sandy, WikiWorks
Signature 2
Reviewed Marked as Reviewed by Peace Sandy on 2024-4-9
Source: Figure S1
Description: Representation of the most significant (FDR < 0.01) classified taxonomic alterations between Parkinson’s disease (PD) and controls.
Abundance in Group 1: decreased abundance in
Experiment 2
Needs review
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Diseased Controls
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with Early-stage L-DOPA-Naive Parkinson's Disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 14
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Peace Sandy on 2024-4-9
Source: Figure S1
Description: Representation of the most significant (FDR < 0.01) classified taxonomic alterations between Parkinson’s disease (PD) and Diseased Controls(DC)
Abundance in Group 1: increased abundance in Patients with Parkinson's Disease
Revision editor(s): Raihanat, Peace Sandy, WikiWorks
Signature 2
Reviewed Marked as Reviewed by Peace Sandy on 2024-4-9
Source: Figure S1
Description: Representation of the most significant (FDR < 0.01) classified taxonomic alterations between Parkinson’s disease (PD) and Diseased Controls (DC)
Abundance in Group 1: decreased abundance in Patients with Parkinson's Disease
Revision editor(s): Raihanat, Peace Sandy, WikiWorks
Retrieved from "https://bugsigdb.org/w/index.php?title=33657381&oldid=153784"
